Angiogenin as a molecular target for the Treatment of Prostate Cancer

Current Cancer Therapy Reviews

Volumn 7, Issue 2, 2011, Pages 83-90

  Li, Shuping ^a   Ibaragi, Soichiro ^a   Hu, Guo Fu ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Androgen independence; Angiogenesis; Angiogenin; Prostate cancer; rRNA transcription

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; ANDROGEN; ANDROGEN RECEPTOR; ANGIOGENESIS INHIBITOR; ANGIOGENIN; ANGIOGENIN INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BINDING PROTEIN; CORTICOSTEROID; ENZYME INHIBITOR; ESTROGEN; FLUTAMIDE; GENTAMICIN; KANAMYCIN; MONOCLONAL ANTIBODY; NEAMINE; NEOMYCIN; PAROMOMYCIN; PROTEIN KINASE B; RIBOSOME DNA; RIBOSOME RNA; SMALL INTERFERING RNA; STREPTOMYCIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; MOLECULARLY TARGETED THERAPY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RECOMMENDED DRUG DOSE; RNA TRANSCRIPTION; TUMOR XENOGRAFT; UPREGULATION;

EID: 79953784016     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/1573394711107020083     Document Type: Article

References (79)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Tan WW. Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control 2006; 13: 194-8.
3. Sinibaldi VJ. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. Clin Interv Aging 2007; 2: 555-60.
4. Taplin ME. Androgen receptor: role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther 2008; 8: 1495-508.
5. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8: 440-8.
6. Feldman BJ, Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
7. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008; 6: e001.
8. Wang Q, Li W, Liu XS, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27: 380-92.
9. Rosenwald IB. Deregulation of protein synthesis as a mechanism of neoplastic transformation. Bioessays 1996; 18: 243-50.
10. Mainwaring WI, Wilce PA. The control of the form and function of the ribosomes in androgen-dependent tissues by testosterone. Biochem J 1973; 134: 795-805.
11. Mainwaring WI, Derry NS. Enhanced transcription of rRNA genes by purified androgen receptor complexes in vitro. J Steroid Biochem 1983; 19: 101-8.
12. Kabler RL, Srinivasan A, Taylor LJ, Mowad J, Rothblum LI, Cavanaugh AH. Androgen regulation of ribosomal RNA synthesis in LNCaP cells and rat prostate. J Steroid Biochem Mol Biol 1996; 59: 431-9.
13. Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA 2006; 103: 14519-24.
14. Ibaragi S, Yoshioka N, Kishikawa H, et al. Angiogenin-stimulated ribosomal RNA transcription is essential for initiation and survival of AKT-induced prostate intraepithelial neoplasia. Mol Cancer Res 2009; 7: 415-24.
15. Ibaragi S, Yoshioka N, Li S, et al. Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated ribosomal RNA transcription. Clin Cancer Res 2009; 15: 1981-8.
16. Fett JW, Strydom DJ, Lobb RR, et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985; 24: 5480-6.
17. Olson KA, Fett JW, French TC, Key ME, Vallee BL. Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA 1995; 92: 442-6.
18. Olson KA, Byers HR, Key ME, Fett JW. Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin. Clin Cancer Res 2001; 7: 3598-605.
19. Tello-Montoliu A, Patel JV, Lip GY. Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost 2006; 4: 1864-74.
20. Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L. Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res 2005; 11: 8358-63.
21. Majumder PK, Yeh JJ, George DJ, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci USA 2003; 100: 7841-6.
22. Olson KA, Byers HR, Key ME, Fett JW. Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody. Int J Cancer 2002; 98: 923-9.
23. Weiner HL, Weiner LH, Swain JL. Tissue distribution and developmental expression of the messenger RNA encoding angiogenin. Science 1987; 237: 280-2.
24. Shimoyama S, Gansauge F, Gansauge S, Negri G, Oohara T, Beger HG. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 1996; 56: 2703-6.
25. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 1999; 86: 316-24.
26. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-55.
27. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirusbased system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-6.
28. Xu ZP, Tsuji T, Riordan JF, Hu GF. Identification and characterization of an angiogenin-binding DNA sequence that stimulates luciferase reporter gene expression. Biochemistry 2003; 42: 121-8.
29. Hu G, Xu C, Riordan JF. Human angiogenin is rapidly translocated to the nucleus of human umbilical vein endothelial cells and binds to DNA. J Cell Biochem 2000; 76: 452-62.
30. Kishimoto K, Liu S, Tsuji T, Olson KA, Hu GF. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 2005; 24: 445-56.
31. Campbell SC. Advances in angiogenesis research: relevance to urological oncology. J Urol 1997; 158: 1663-74.
32. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998; 44: 705-23.
33. Ferrer FA, Miller LJ, Andrawis RI, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells [see comments]. J Urol 1997; 157: 2329-33.
34. Hatzi E, Bassaglia Y, Badet J. Internalization and processing of human angiogenin by cultured aortic smooth muscle cells [In Process Citation]. Biochem Biophys Res Commun 2000; 267: 719-25.
35. Xu ZP, Tsuji T, Riordan JF, Hu GF. The nuclear function of angiogenin in endothelial cells is related to rRNA production. Biochem Biophys Res Commun 2002; 294: 287-92.
36. Moroianu J, Riordan JF. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc Natl Acad Sci USA 1994; 91: 1677-81.
37. Tsuji T, Y. S, Kishimoto K, et al. Angiogenin is translocated to the nucleus of HeLa cells and is involved in rRNA transcription and cell proliferation. Cancer Res 2005; 65: 1352-60.
38. Hu GF. Neomycin inhibits angiogenin-induced angiogenesis. Proc Natl Acad Sci USA 1998; 95: 9791-5.
39. Somjen D, Kohen F, Lieberherr M. Nongenomic effects of an antiidiotypic antibody as an estrogen mimetic in female human and rat osteoblasts. J Cell Biochem 1997; 65: 53-66.
40. Hildebrandt JP, Plant TD, Meves H. The effects of bradykinin on K+ currents in NG108-15 cells treated with U73122, a phospholipase C inhibitor, or neomycin. Br J Pharmacol 1997; 120: 841-50.
41. Glasby JS. Encyclopedia of antibiotics. New York, NY: John Wiley & Sons Ltd; 1993; pp. 363-7.
42. Leach BE, Teeters CM. Neamine, an antibacterial degradation product of neomycin. J Am Chem Soc 1951; 73: 2794-7.
43. Hirukawa S, Olson KA, Tsuji T, Hu GF. Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice. Clin Cancer Res 2005; 11: 8745-52.
44. Williams PD, Bennett DB, Gleason CR, Hottendorf GH. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother 1987; 31: 570-4.
45. Au S, Weiner N, Schacht J. Membrane perturbation by aminoglycosides as a simple screen of their toxicity. Antimicrob Agents Chemother 1986; 30: 395-7.
46. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-6.
47. Gregory CW, Johnson RT, Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892-8.
48. Labrie F, Dupont A, Belanger A, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 1986; 7: 67-74.
49. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001; 7: 1273-81.
50. Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944-9.
51. Gaddipati JP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994; 54: 2861-4.
52. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59: 2511-5.
53. Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992; 41: 665-9.
54. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6: 703-6.
55. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999; 20: 321-44.
56. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-8.
57. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 1999; 274: 7777-83.
58. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996; 271: 19900-7.
59. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999; 59: 279-84.
60. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999; 96: 5458-63.
61. Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000; 275: 24500-5.
62. Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgenindependent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60: 6841-5.
63. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64: 9209-16.
64. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4.
65. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosissuppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143: 390-400.
66. Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999; 5: 2891-8.
67. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996; 2: 389-98.
68. Culig Z, Hobisch A, Cronauer MV, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996; 28: 392-405.
69. Adam RM, Kim J, Lin J, et al. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 2002; 143: 4599-608.
70. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-90.
71. Trotman LC, Niki M, Dotan ZA, et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003; 1: E59.
72. Sellers WR, Sawyers CA. The somatic genetics of prostate cancer. In: Prostate cancer principles and practice. Kantoff PW Ed. Philadephia: Lippincott Williams & Wilkins; 2002.
73. Sun M, Wang G, Paciga JE, et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-7.
74. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601.
75. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA 2001; 98: 136-41.
76. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 1997; 16: 3693-704.
77. Terada N, Patel HR, Takase K, Kohno K, Nairn AC, Gelfand EW. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci USA 1994; 91: 11477-81.
78. Waksman SA, Lechevalier HA. Neomycin, a new antibiotic active against streptomycin-resistant bacteria, including tuberculosis organisms. Science 1949; 109: 305-7.
79. th ed. New York: McGraw-Hill 1971. p. 749.